about
Impact of gene dosage on gene expression, biological processes and survival in cervical cancer: a genome-wide follow-up study.Amplified genes may be overexpressed, unchanged, or downregulated in cervical cancer cell lines.Trisomy 1q41-qter and monosomy 3p26.3-pter in a family with a translocation (1;3): further delineation of the syndromes.The distribution of high-risk human papillomaviruses is different in young and old patients with cervical cancerMitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer.19q13.11 microdeletion concomitant with ins(2;19)(p25.3;q13.1q13.4)dn in a boy: potential role of UBA2 in the associated phenotypeCDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical CancerDifferent Association of Human Papillomavirus 16 Variants with Early and Late Presentation of Cervical CancerTargeting CDKN3 in cervical cancer.Biochemical and proteomic analysis of spliceosome factors interacting with intron-1 of human papillomavirus type-16.Let-7c overexpression inhibits dengue virus replication in human hepatoma Huh-7 cells.A few nucleotide polymorphisms are sufficient to recruit nuclear factors differentially to the intron 1 of HPV-16 intratypic variants.The HPV-16 E7 oncoprotein is expressed mainly from the unspliced E6/E7 transcript in cervical carcinoma C33-A cells.A great diversity of Amerindian mitochondrial DNA ancestry is present in the Mexican mestizo population.Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation.A pilot study in patients with established advanced liver fibrosis using pirfenidoneThe presence of aflatoxin B₁-FAPY adduct and human papilloma virus in cervical smears from cancer patients in Mexico.Genome amplification of human papillomavirus types 16 and 18 in cervical carcinomas is related to the retention of E1/E2 genes.Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16 E6 and E7 oncoproteins in sera of cervical cancer patients.The E7 protein of human papillomavirus (HPV) type 16 expressed by recombinant vaccinia virus can be used for detection of antibodies in sera from cervical cancer patients.Enhanced oncogenicity of Asian-American human papillomavirus 16 is associated with impaired E2 repression of E6/E7 oncogene transcription.C33-A cells transfected with E6*I or E6*II the short forms of HPV-16 E6, displayed opposite effects on cisplatin-induced apoptosis.Amplification of human papillomavirus types 16 and 18 in invasive cervical cancer.Frequency of haplotypes in the beta globin gene cluster in a selected sample of the mexican population.HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients.Diagnosis of familial Wolf-Hirschhorn syndrome due to a paternal cryptic chromosomal rearrangement by conventional and molecular cytogenetic techniquesAssociation between human papillomavirus type 18 variants and histopathology of cervical cancer.Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control studyFunctional expression of voltage-gated sodium channels in primary cultures of human cervical cancerWide allelic heterogeneity with predominance of large IDS gene complex rearrangements in a sample of Mexican patients with Hunter syndromeHPV-16 and HLA-DRB1 alleles are associated with cervical carcinoma in Mexican Mestizo women
P50
Q33690029-AF64F486-2C1A-4145-9F10-ED098B874F4DQ34193299-18D2F820-0BBC-4A58-99DD-DDCD82643FF2Q34219236-E05E50BD-95DE-4D0E-BC5E-E9102779E55BQ34308427-D49516BC-5F74-4E52-894D-1197A0E11916Q34584632-BF26393D-4933-46B9-BF80-1568EE5DBADCQ34707139-FD0B0322-C7D1-4675-B7E1-451D6998D0F3Q35776083-AB1EAD7B-0BF1-4633-8B30-69A6548B1CDEQ36236454-67CE2DFE-8D66-4FA2-B679-E27280CBE293Q38242742-BA4DB502-09E8-4C68-BC44-F68B431270D6Q38305124-60B354A0-02AD-40FA-B057-847A7EC666DAQ38935932-2654C3B7-ADB8-4280-AE07-82445D7FF929Q39378353-7DD7F49E-BECC-4805-8596-6C026045A778Q39652069-867EC9C9-A7F4-48B8-883B-1B127A3432DFQ39938178-C4492171-F1CA-458B-B813-89A661E3A145Q40747726-EB4F02ED-4089-4B46-94AE-551D827E800EQ42836019-DE8BF96B-E14D-4384-959B-CCD69E605468Q43547424-FE722A00-9A61-424A-ACD5-DD3148017166Q44114428-D2E64610-E730-4E1F-973B-C20CA6CAFA5EQ44489254-214351EA-330E-4938-A4FE-BDBACBF859E1Q45766529-FDD0F200-287D-4B23-908D-875A4FE33F48Q47421360-489C0870-FF1B-4665-A858-BA763B6FBDDAQ49923280-735C36E3-DC1C-4B23-84DB-53BE61309DBEQ51194840-12400706-F18F-4A6B-A2C2-998C735322B8Q53154562-95E75934-AB3E-4E76-BA01-4FA1493E6B35Q54690022-509BAF23-1404-47D1-ABF4-8891773ED775Q58920516-3F447E09-E0D1-487E-9F69-8A8184312A5EQ64936568-35FBB72E-E528-46C9-BEA0-3880090E9AA3Q74459615-0771F739-95D5-439F-B33E-B94CBC5DD561Q79274012-A0C8CB59-9CC6-4E20-8590-F9F7A0AC32A3Q87070180-636728EE-2B23-412B-A52B-1C5FC0B32217Q95380319-9E6C440E-86AA-4362-A458-850444671C6B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jaime Berumen
@ast
Jaime Berumen
@en
Jaime Berumen
@es
Jaime Berumen
@nl
type
label
Jaime Berumen
@ast
Jaime Berumen
@en
Jaime Berumen
@es
Jaime Berumen
@nl
prefLabel
Jaime Berumen
@ast
Jaime Berumen
@en
Jaime Berumen
@es
Jaime Berumen
@nl
P106
P1153
6603045594
P31
P496
0000-0001-6707-3317